The following information is intended as a resource for journalists only and was factually correct at the time it was issued.
Kate Richards
Head of Corporate Communications
Australia
and New Zealand
+61 466 420 739
kate.richards@abbvie.com
AbbVie Australia follows Medicines Australia’s Code of Conduct and the Therapeutic Goods Act. Both prohibit a pharmaceutical company from direct to consumer advertising which includes issuing media statements about our prescription medicines. We can issue statements to advise registration of a new medicine, a reimbursement notice of a medicine or news not related to our medicines.
New option for Australians with certain autoimmune diseases through
reimbursement of HUMIRA® (adalimumab) citrate-free formulation
Read
full media release here.
Read pdf version of the full media release here.
Venclexta (venetoclax) PBS listed as first line therapy for Chronic
Lymphocytic Leukaemia (CLL) patients unfit for chemotherapy
Read
full media release here.
Read pdf version of the full media release here.
AbbVie collaborates with BioCurate to accelerate commercialisation
of Australian novel early stage discoveries into new therapeutics
and drugs
Read
full media release here.
Read pdf version of the full media release here.
MAVIRET® is the first PBS listed Hepatitis C treatment available
for Australians 12 years and over
Read full media release here.
Read pdf version of the full media release here.
New treatment for rheumatoid arthritis, RINVOQ (upadacitinib),
became available on the PBS during COVID-19 lockdown
Read full media release here.
AbbVie reinvents ‘pharma culture’ and takes Australia’s #2 spot for
Best Place to Work
Read full media release here.
AbbVie Completes Transformative Acquisition of Allergan
Read full media release here.
AbbVie Australia - Local Response to COVID-19
Read here.
AbbVie welcomes Therapeutic Goods Administration (TGA) Regulatory
Approval of RINVOQ® (upadacitinib)
Read full media release here.
Chris Stemple Appointed General Manager AbbVie ANZ
Read full media release here.
New biologic option for severe plaque psoriasis now available on
Pharmaceutical Benefits Scheme
Read full media release here.
AbbVie welcomes Therapeutic Goods Administration (TGA) Regulatory
Approval of SKYRIZI™ (risankizumab)
Read full media release here.
AbbVie ANZ Appoints New Medical Director
Read full media release here.
New targeted treatment option for patients with Chronic Lymphocytic
Leukaemia (CLL) now available on the Pharmaceutical Benefits Scheme
Read full media release here.
AbbVie Welcomes TGA Regulatory Approval of VENCLEXTA® (venetoclax
tablets) in Combination with Rituximab
Read full media release here.
Eight-week Hepatitis C Treatment on Pharmaceutical
Benefits scheme from 1st August 2018
Read full media release here.
Announcement: Venclexta PBS Status
Read full media release here.
Experts concerned Parksinon’s patients may be missing out on
support in the Illawarra
Read full media release here.
